"Purchase complete, lawyers working on forms" Of
Post# of 30066
(Total Views: 359)
Posted On: 07/02/2021 5:12:15 AM
"Purchase complete, lawyers working on forms"
Of Todos shares
Gerald posted today on Twitter
https://twitter.com/G_Commish/status/14106081...62952?s=01
We'll see how much and how, could give a nice boost of confidence.
Anything good for Todos is helpful to Amarantus and anything good especially for LymPro is really good for Amarantus.
85,586,795 Todos shares owned by AMARANTUS ,
In addition a 10% royalty on LymPro intellectual property.
(LymPro Test™has been valued at $136 million by an independent third-party valuation firm...)
Todos Corporate Profile: Videssa™ Breast Cancer, LymPro Alzheimer’s blood tests and Revenue...
Additionally, the recent approval of Biogen’s Aduhelm™ amyloid beta antibody has significantly increased the value of the Company’s proprietary LymPro Alzheimer’s blood test, that has shown to extremely strong correlation data (p=0.000002) with amyloid beta PET imaging SUVR scores in preliminary studies performed by our partners at Leipzig University in Germany under the direction of Dr. Thomas Arendt. We believe that payers will require patients to undergo amyloid PET imaging prior to prescribing Aduhelm. In the effort to identify those patients who are likely to be positive for PET imaging, and mitigate the negative side effects of the radioactive materials used in the conduct of amyloid PET imaging testing for those unlikely to be amyloid positive, payers will want to pre-screen patients with minimally invasive tools that could give them a higher degree of confidence that a patient will be amyloid beta positive by PET imaging. LymPro could fill this emerging need for physicians and payers, as well as fulfill this area of need for pharmaceutical companies seeking to enrich their screening for clinical trials. Given the $250 billion marketplace for Alzheimer’s that is expected to grow rapidly as new treatment options continue to get market authorization in the US, we believe LymPro could also help drive mid-term value for Todos as progress is made.
In support of the Company’s proprietary Videssa and LymPro tests, Todos will continue to be focused on generating revenue through the sale of diagnostic tests, with a greater emphasis being placed on expanding diagnostic testing services provided to the marketplace through Provista’s CLIA/CAP certified lab due to the increased margins vs. the reagents sales business. The reason why lab services represents a much more attractive business than reagents sales is because the margins per test are 10-15x higher per test on revenues that are 4-10x higher per test than selling regents. From a financial forecasting standpoint, free cash flow generated from $10M in sales from lab sales of COVID-19 testing services would be close to $7M on the sale of 100,000-125,000 tests, whereas free cash generated from $10M in sales of reagents would be $4M on sales ~500,000 tests. As such, we see the acquisition of samples for Provista as the next natural evolution in our CLIA testing strategy in order to support the ultimate commercialization and market acceptance of our proprietary Videssa and LymPro blood tests.
https://investor.todosmedical.com/news-events...-corporate
Todos and Amarantus JV Announces Full Enrollment for Clinical Trial of LymPro Alzheimer’s Blood Test Relationship with Amyloid PET
November 14, 2019
https://ca.finance.yahoo.com/news/todos-amara...00029.html
Sitting back waiting.
Of Todos shares
Gerald posted today on Twitter
https://twitter.com/G_Commish/status/14106081...62952?s=01
We'll see how much and how, could give a nice boost of confidence.
Anything good for Todos is helpful to Amarantus and anything good especially for LymPro is really good for Amarantus.
85,586,795 Todos shares owned by AMARANTUS ,
In addition a 10% royalty on LymPro intellectual property.
(LymPro Test™has been valued at $136 million by an independent third-party valuation firm...)
Todos Corporate Profile: Videssa™ Breast Cancer, LymPro Alzheimer’s blood tests and Revenue...
Additionally, the recent approval of Biogen’s Aduhelm™ amyloid beta antibody has significantly increased the value of the Company’s proprietary LymPro Alzheimer’s blood test, that has shown to extremely strong correlation data (p=0.000002) with amyloid beta PET imaging SUVR scores in preliminary studies performed by our partners at Leipzig University in Germany under the direction of Dr. Thomas Arendt. We believe that payers will require patients to undergo amyloid PET imaging prior to prescribing Aduhelm. In the effort to identify those patients who are likely to be positive for PET imaging, and mitigate the negative side effects of the radioactive materials used in the conduct of amyloid PET imaging testing for those unlikely to be amyloid positive, payers will want to pre-screen patients with minimally invasive tools that could give them a higher degree of confidence that a patient will be amyloid beta positive by PET imaging. LymPro could fill this emerging need for physicians and payers, as well as fulfill this area of need for pharmaceutical companies seeking to enrich their screening for clinical trials. Given the $250 billion marketplace for Alzheimer’s that is expected to grow rapidly as new treatment options continue to get market authorization in the US, we believe LymPro could also help drive mid-term value for Todos as progress is made.
In support of the Company’s proprietary Videssa and LymPro tests, Todos will continue to be focused on generating revenue through the sale of diagnostic tests, with a greater emphasis being placed on expanding diagnostic testing services provided to the marketplace through Provista’s CLIA/CAP certified lab due to the increased margins vs. the reagents sales business. The reason why lab services represents a much more attractive business than reagents sales is because the margins per test are 10-15x higher per test on revenues that are 4-10x higher per test than selling regents. From a financial forecasting standpoint, free cash flow generated from $10M in sales from lab sales of COVID-19 testing services would be close to $7M on the sale of 100,000-125,000 tests, whereas free cash generated from $10M in sales of reagents would be $4M on sales ~500,000 tests. As such, we see the acquisition of samples for Provista as the next natural evolution in our CLIA testing strategy in order to support the ultimate commercialization and market acceptance of our proprietary Videssa and LymPro blood tests.
https://investor.todosmedical.com/news-events...-corporate
Todos and Amarantus JV Announces Full Enrollment for Clinical Trial of LymPro Alzheimer’s Blood Test Relationship with Amyloid PET
November 14, 2019
https://ca.finance.yahoo.com/news/todos-amara...00029.html
Sitting back waiting.
(1)
(0)